Spectral Medical Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Spectral Medical Inc.

EDTXF 0.410

-1.7%

Oct 11 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Sultan	8/1/2024 1:07:35 PM
	of 483

Spectral Medical Provides July Tigris Trial Update • 125 patients enrolled • Record July patient enrollment to start the second half of 2024 TORONTO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment to start the second half of 2024, which continues the pace experienced since January 2024: 125 patients enrolled at end of July 2024 Record monthly enrollment with nine patients enrolled in July – equals monthly enrollment record set in June 44 patients enrolled in 2024 so far – represents the most robust enrollment rates since the start of the Tigris study With 25 patients to full enrollment, the Company has entered the final push to fully enroll and finish the Tigris trial Based on current rate of enrollment, Tigris could be completed as early as December 2024 Trial Sites: Currently 23 clinical sites Spectral clinical team focused on trial site management activities to ensure that Tigris sites have the support and resources to enroll patients as efficiently as possible Dr. John Kellum, Chief Medical Officer of Spectral, noted, “Tigris is gathering momentum as we enter the final months of the trial. We have a very strong group of sites and very dedicated investigators. We could not ask for a better team.”

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next